IP Library Granted Patent US 11,938,117
Granted Patent B2
US 11,938,117 · App. 15/693,223 · Granted Mar 26, 2024

Magnesium biotinate compositions and methods of use

Inventors: Deanna J. Nelson (Raleigh, NC); James R. Komorowski (Trumbull, CT)
Assignee: Nutrition21, LLC
A61K31/4188A61K8/19A61K8/673A61K9/0053A61K9/2086A61K9/28A61K9/2806A61Q3/00A61Q5/002A61Q7/00A61K2800/58
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,938,117
App. No.
15/693,223
Granted
Mar 26, 2024
Kind
B2
Abstract

The present application relates to magnesium biotinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable biotin to mammals and treating or preventing symptoms of biotin deficiency.

Claims (43)

1. A powder composition comprising:

isolated crystalline or isolated amorphous magnesium biotinate; and

optionally a pharmaceutically acceptable vehicle, carrier, or diluent.

2. The powder composition of claim 1 , comprising 10 mg of magnesium biotinate.

3. The powder composition of claim 1 , wherein the magnesium biotinate is magnesium D-biotinate.

4. The powder composition of claim 1 , wherein the magnesium biotinate is enriched with respect to the D-enantiomer.

5. A dosage form comprising the powder composition of claim 1 .

6. A powder composition comprising:

from 10 mg to 100 mg of isolated crystalline or isolated amorphous magnesium biotinate;

an additional therapeutic agent; and

optionally a pharmaceutically acceptable vehicle, carrier, or diluent.

7. The powder composition of claim 6 , comprising 10 mg of the magnesium biotinate.

8. The powder composition of claim 6 , wherein the magnesium biotinate is magnesium D-biotinate.

9. The powder composition of claim 6 , wherein the magnesium biotinate is enriched with respect to the D-enantiomer.

10. A dosage form comprising the powder composition of claim 6 .

11. A powder composition comprising:

isolated crystalline or isolated amorphous magnesium biotinate;

optionally an additional therapeutic agent; and

optionally a pharmaceutically acceptable vehicle, carrier, or diluent;

wherein the magnesium biotinate is at least 3.9 wt % magnesium.

12. The powder composition of claim 11 , comprising from 10 mg to 100 mg of the magnesium biotinate.

13. The powder composition of claim 11 , comprising 10 mg of the magnesium biotinate.

14. The powder composition of claim 11 , wherein the magnesium biotinate is magnesium D-biotinate.

15. The powder composition of claim 11 , wherein the magnesium biotinate is enriched with respect to the D-enantiomer.

16. A dosage form comprising the powder composition of claim 11 .

17. A dosage form comprising:

an effective amount of isolated crystalline or isolated amorphous magnesium biotinate; and

optionally a pharmaceutically acceptable vehicle, carrier, or diluent;

wherein said effective amount is sufficient to deliver 10 mg of biotin to a subject.

18. The dosage form of claim 17 , wherein said effective amount is from 10 mg to 100 mg of the magnesium biotinate.

19. The dosage form of claim 17 , wherein said effective amount is 10 mg of the magnesium biotinate.

20. The dosage form of claim 17 , wherein the magnesium biotinate is magnesium D-biotinate.

21. The dosage form of claim 17 , wherein the magnesium biotinate is enriched with respect to the D-enantiomer.

22. A dosage form comprising:

an effective amount of isolated crystalline or isolated amorphous magnesium biotinate;

optionally a pharmaceutically acceptable vehicle, carrier, or diluent; and

an additional therapeutic agent;

wherein said effective amount is sufficient to deliver 10 mg of biotin to a subject.

23. The dosage form of claim 22 , wherein said effective amount is from 10 mg to 100 mg of the magnesium biotinate.

24. The dosage form of claim 22 , wherein said effective amount is 10 mg of the magnesium biotinate.

25. The dosage form of claim 22 , wherein the magnesium biotinate is magnesium D-biotinate.

26. The dosage form of claim 22 , wherein the magnesium biotinate is enriched with respect to the D-enantiomer.

27. The powder composition of claim 1 , comprising from 10 mg to 100 mg of the magnesium biotinate.

Assignments (3)
SECURITY INTEREST Recorded Nov 9, 2021
From: NUTRITION 21, LLC
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 058060/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2021
From: JDS THERAPEUTICS, LLC
To: NUTRITION 21, LLC
Reel/Frame 056933/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2017
From: NELSON, DEANNA J.; KOMOROWSKI, JAMES R.
To: JDS THERAPEUTICS, LLC
Reel/Frame 043474/0148 →
Continuity (2)
Provisional Application 62382438 · Sep 1, 2016
Related Publication 20180071264A1 · Mar 15, 2018
Cited By (1)
US 12,257,238